Takeda Pharmaceutical Co. Ltd. Takes $527,000 Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Takeda Pharmaceutical Co. Ltd. purchased a new stake in Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 823,317 shares of the company's stock, valued at approximately $527,000. Lyell Immunopharma comprises 2.0% of Takeda Pharmaceutical Co. Ltd.'s holdings, making the stock its 7th biggest holding. Takeda Pharmaceutical Co. Ltd. owned about 0.28% of Lyell Immunopharma at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in LYEL. JPMorgan Chase & Co. increased its stake in shares of Lyell Immunopharma by 347.8% in the 4th quarter. JPMorgan Chase & Co. now owns 433,265 shares of the company's stock valued at $277,000 after buying an additional 336,516 shares during the period. Charles Schwab Investment Management Inc. increased its position in Lyell Immunopharma by 43.4% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,645,787 shares of the company's stock worth $1,053,000 after purchasing an additional 498,417 shares during the period. SG Americas Securities LLC increased its position in Lyell Immunopharma by 102.8% in the fourth quarter. SG Americas Securities LLC now owns 116,748 shares of the company's stock worth $75,000 after purchasing an additional 59,182 shares during the period. Barclays PLC raised its holdings in Lyell Immunopharma by 312.7% during the 3rd quarter. Barclays PLC now owns 240,615 shares of the company's stock worth $332,000 after purchasing an additional 182,315 shares during the last quarter. Finally, Jane Street Group LLC lifted its position in Lyell Immunopharma by 63.7% during the 3rd quarter. Jane Street Group LLC now owns 287,717 shares of the company's stock valued at $397,000 after purchasing an additional 111,917 shares during the period. Institutional investors and hedge funds own 66.05% of the company's stock.

Insider Buying and Selling

In other Lyell Immunopharma news, Director Richard Klausner acquired 158,000 shares of the company's stock in a transaction that occurred on Friday, March 14th. The shares were acquired at an average price of $0.60 per share, with a total value of $94,800.00. Following the purchase, the director now owns 843,365 shares of the company's stock, valued at $506,019. This represents a 23.05 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Lynn Seely bought 175,000 shares of the firm's stock in a transaction on Friday, March 14th. The stock was acquired at an average cost of $0.61 per share, with a total value of $106,750.00. Following the completion of the purchase, the chief executive officer now owns 712,500 shares of the company's stock, valued at approximately $434,625. This trade represents a 32.56 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought 733,000 shares of company stock valued at $429,550 in the last 90 days. 25.10% of the stock is owned by insiders.

Lyell Immunopharma Trading Down 4.1 %

Shares of NASDAQ:LYEL traded down $0.02 during midday trading on Monday, hitting $0.52. The company had a trading volume of 236,825 shares, compared to its average volume of 1,021,755. Lyell Immunopharma, Inc. has a 12 month low of $0.48 and a 12 month high of $3.15. The firm has a fifty day simple moving average of $0.61 and a 200 day simple moving average of $0.86. The stock has a market cap of $153.22 million, a price-to-earnings ratio of -0.66 and a beta of -0.41.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last issued its earnings results on Wednesday, March 12th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.52). The company had revenue of $0.01 million for the quarter. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. Equities analysts forecast that Lyell Immunopharma, Inc. will post -0.78 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a "neutral" rating and set a $1.00 price target on shares of Lyell Immunopharma in a research report on Thursday, March 13th.

Lyell Immunopharma Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.